首站-论文投稿智能助手
典型文献
Combination of Se-methylselenocysteine, D-α-tocopheryl succinate,β-carotene, and L-lysine can prevent cancer metastases using as an adjuvant therapy
文献摘要:
Objective:Primary tumor treatment through surgical resection and adjuvant therapy has been extensively studied, but there is a lack of effective strategies and drugs for the treatment of tumor metastases. Here, we describe a functional product based on a combination of compounds, which can be used as an adjuvant therapy and has well-known mechanisms for inhibiting cancer metastases, improving anti-cancer treatment, and enhancing immunity and antioxidant capacity. Our designed combination, named MVBL, consists of four inexpensive compounds: L-selenium-methylselenocysteine (MSC), D-α-tocopheryl succinic acid (VES), β-carotene (β-Ca), and L-lysine (Lys). Methods:The effects of MVBL on cell viability, cell cycle, cell apoptosis, cell migration, cell invasion, reactive oxygen species (ROS), and paclitaxel (PTX)-combined treatment were studied in vitro. The inhibition of tumor metastasis, antioxidation, and immune enhancement capacity of MVBL were determined in vivo. Results:MVBL exhibited higher toxicity to tumor cells than to normal cells. It did not significantly affect the cell cycle of cancer cells, but increased their apoptosis. Wound healing, adhesion, and transwell assays showed that MVBL significantly inhibited tumor cell migration, adhesion, and invasion. MVBL sensitized MDA-MB-231 breast cancer cells to PTX, indicating that it can be used as an adjuvant to enhance the therapeutic effect of chemotherapy drugs. In mice, experimental data showed that MVBL inhibited tumor metastasis, prolonged their survival time, and enhanced their antioxidant capacity and immune function. Conclusions:This study revealed the roles of MVBL in improving immunity and antioxidation, preventing tumor growth, and inhibiting metastasis in vitro and in vivo. MVBL may be used as an adjuvant drug in cancer therapy for improving the survival and quality of life of cancer patients.
文献关键词:
作者姓名:
Yunlong CHENG;Shu LIAN;Shuhui LI;Yusheng LU;Jie WANG;Xiaoxiao DENG;Shengyi ZHAI;Lee JIA
作者机构:
Fujian-Taiwan-Hongkong-Macao Science and Technology Cooperation Base of Intelligent Pharmaceutics,College of Materials and Chemical Engineering,Minjiang University,Fuzhou 350108,China;Cancer Metastasis Alert and Prevention Center,Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention,College of Chemistry,Fuzhou University,Fuzhou 350002,China;Fuzhou Institute of Oceanography,Minjiang University,Fuzhou 350108,China
引用格式:
[1]Yunlong CHENG;Shu LIAN;Shuhui LI;Yusheng LU;Jie WANG;Xiaoxiao DENG;Shengyi ZHAI;Lee JIA-.Combination of Se-methylselenocysteine, D-α-tocopheryl succinate,β-carotene, and L-lysine can prevent cancer metastases using as an adjuvant therapy)[J].浙江大学学报(英文版)(B辑:生物医学和生物技术),2022(11):943-956,13-18
A类:
methylselenocysteine,tocopheryl,MVBL
B类:
Combination,Se,succinate,carotene,lysine,cancer,metastases,using,adjuvant,Objective,Primary,tumor,treatment,through,surgical,resection,has,been,extensively,studied,but,there,lack,effective,strategies,drugs,Here,describe,functional,product,combination,compounds,which,used,known,mechanisms,inhibiting,improving,enhancing,immunity,antioxidant,capacity,Our,designed,named,consists,four,inexpensive,selenium,MSC,succinic,acid,VES,Lys,Methods,effects,viability,cycle,apoptosis,migration,invasion,reactive,oxygen,species,ROS,paclitaxel,PTX,combined,were,vitro,inhibition,metastasis,antioxidation,immune,enhancement,determined,vivo,Results,exhibited,higher,toxicity,cells,than,normal,It,did,not,significantly,affect,increased,their,Wound,healing,adhesion,transwell,assays,showed,that,inhibited,sensitized,MB,breast,indicating,therapeutic,chemotherapy,In,mice,experimental,data,prolonged,survival,enhanced,Conclusions,This,study,revealed,roles,preventing,growth,may,quality,life,patients
AB值:
0.471609
相似文献
Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
Xinyi Zhou;Qian Xiao;Dongliang Fu;Haochen Zhang;Yang Tang;Jinjie He;Yeting Hu;Xiangxing Kong;Fei Teng;Xiangrui Liu;Ying Yuan;Kefeng Ding-Department of Colorectal Surgery and Oncology,Key Laboratory of Cancer Prevention and Intervention,Ministry of Education,the Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China;Department of Medical Oncology,Key Laboratory of Cancer Prevention and Intervention,Ministry of Education,the Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China;Hangzhou Oncocare Co Ltd,Hangzhou 310009,China;Department of Pharmacology,Zhejiang University School of Medicine,Hangzhou 310058,China;Cancer Center,Zhejiang University,Hangzhou 310009,China
Systematic screening reveals synergistic interactions that overcome MAPK inhibitor resistance in cancer cells
Yu Yu;Minzhen Tao;Libin Xu;Lei Cao;Baoyu Le;Na An;Jilin Dong;Yajie Xu;Baoxing Yang;Wei Li;Bing Liu;Qiong Wu;Yinying Lu;Zhen Xie;Xiaohua Lian-Department of Cell Biology,Basic Medical College,Army Medical University(Third Military Medical University),Chongqing 400038,China;MOE Key Laboratory of Bioinformatics and Bioinformatics Division,Center for Synthetic and System Biology,Department of Automation,Beijing National Research Center for Information Science and Technology,Tsinghua University,Beijing 100084,China;National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Thoracic Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China;Beijing Syngentech Co.,Ltd,Beijing 102206,China;School of Life Sciences,Tsinghua University,Beijing 100084,China;The Comprehensive Liver Cancer Center,The 5th Medical Center of PLA General Hospital,Beijing 100039,China
JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKK β
Zilu Zhang;Chenjing Ye;Jia Liu;Wenbin Xu;Chao Wu;Qing Yu;Xiaoguang Xu;Xinyi Zeng;Huizi Jin;Yingli Wu;Hua Yan-Shanghai Institute of Hematology,Affiliated Ruijin Hospital of Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;VIP Health Center,Affiliated Ruijin Hospital of Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs,School of Pharmacy,Shanghai Jiao Tong University,Shanghai 200240,China;Hongqiao International Institute of Medicine,Shanghai Tongren Hospital/Faculty of Basic Medicine,Chemical Biology Division of Shanghai Universities E-Institutes,Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
Tingting Feng;Jing Wang;Kai Cheng;Qiqi Lu;Ru Zhao;Shiguan Wang;Qingyun Zhang;Luna Ge;Jihong Pan;Guanhua Song;Lin Wang-Department of Pathology,School of Basic Medical Sciences,Shandong University,Jinan 250012,China;Department of Pathology,The Fourth People's Hospital of Jinan,Jinan 250031,China;Department of PET-CT,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250002,China;The Second Hospital,Cheeloo College of Medicine,Shandong University Medical School,Jinan 250012,China;Biomedical Sciences College&Shandong Medicinal Biotechnology Centre,Key Lab for Biotech-Drugs of National Health Commission,Key Lab for Rare&Uncommon Diseases of Shandong Province,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Biochemistry and Molecular Biology,Shandong University School of Basic Medical Sciences,Jinan 250012,China;Institute of Basic Medicine,Shandong Academy of Medical Sciences,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Oncology,The First Affiliated Hospital of Shandong First Medical University,Jinan 250014,China
A causal variant rs3769823 in 2q33.1 involved in apoptosis pathway leading to a decreased risk of non-small cell lung cancer
Xu Zhang;Na Qin;Jingyi Fan;Chang Zhang;Qi Sun;Yayun Gu;Meng Zhu;Erbao Zhang;Juncheng Dai;Guangfu Jin;Hongxia Ma;Zhibin Hu;Hongbing Shen-Department of Epidemiology,Center for Global Health,School of Public Health,Nanjing Medical University,Nanjing 211166,China;Jiangsu Key Lab of Cancer Biomarkers,Prevention and Treatment,Collaborative Innovation Center for Cancer Personalized Medicine,Nanjing Medical University,Nanjing 211166,China;Health Management Center,The Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou Municipal Hospital,Gusu School,Nanjing Medical University,Suzhou 215008,China;Research Units of Cohort Study on Cardiovascular Diseases and Cancers,Chinese Academy of Medical Sciences,Beijing 100730,China
Exosomal miR-485-3p derived from pancreatic ductal epithelial cells inhibits pancreatic cancer metastasis through targeting PAK1
Li Mingzhe;Zhou Jiaxin;Zhang Zhengkui;Li Jisong;Wang Feng;Ma Ling;Tian Xiaodong;Mao Zebin;Yang Yinmo-Department of General Surgery, Peking University First Hospital, Beijing 100034, China;Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang 310016, China;Department of Gastrointestinal Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China;Department of Surgical Oncology, Peking University Ninth School of Clinical Medicine (Beijing Shijitan Hospital, Capital Medical University), Beijing 100038, China;Department of Medical Biochemistry and Molecular Biology, Peking University Health Science Center, Beijing 100191, China
Bioresponsive immune-booster-based prodrug nanogel for cancer immunotherapy
Xianbin Ma;Shaochen Yang;Tian Zhang;Shuo Wang;Qichao Yang;Yao Xiao;Xiaoxiao Shi;Peng Xue;Yuejun Kang;Gang Liu;Zhi-Jun Sun;Zhigang Xu-Key Laboratory of Luminescence Analysis and Molecular Sensing(Southwest University),Ministry of Education,School of Materials and Energy & Chongqing Engineering Research Center for Micro-Nano Biomedical Materials and Devices,Southwest University,Chongqing 400715,China;The State Key Laboratory Breeding Base of Basic Science of Stomatology(Hubei-MOST) & Key Laboratory of Oral Biomedicine,Ministry of Education,School and Hospital of Stomatology,Wuhan University,Wuhan 430079,China;State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine,School of Public Health,Xiamen University,Xiamen 361102,China
Natural exosome-like nanovesicles from edible tea flowers suppress metastatic breast cancer via ROS generation and microbiota modulation
Qiubing Chen;Qian Li;Yuqi Liang;Menghang Zu;Nanxi Chen;Brandon S.B.Canup;Liyong Luo;Chenhui Wang;Liang Zeng;Bo Xiao-State Key Laboratory of Silkworm Genome Biology,College of Sericulture,Textile,and Biomass Sciences,Southwest University,Chongqing 400715,China;Chongqing Key Laboratory of Soft-Matter Material Chemistry and Function Manufacturing,School of Materials and Energy,Southwest University,Chongqing 400715,China;Department of Chemistry,Center for Diagnostics and Therapeutics,Georgia State University,Atlanta,GA 30303,USA;College of Food Science,Southwest University,Chongqing 400715,China;Chongqing Key Laboratory of Natural Product Synthesis and Drug Research,School of Pharmaceutical Sciences,Chongqing University,Chongqing 401331,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment
Da-cai Xu;Li Yang;Pei-quan Zhang;Ding Yan;Qian Xue;Qing-tian Huang;Xiao-fen Li;Ya-li Hao;Dao-lin Tang;Q.Ping Dou;Xin Chen;Jin-bao Liu-Affliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;The Department of Physiology,School of Basic Medical Sciences,Guizhou Medical University,Guiyang 550003,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。